Current and future therapeutics targeting mast cells in disease

Area of Science:

• Immunology
• Dermatology
• Oncology

Background:

• Mast cells (MCs) are immune cells implicated in allergic diseases.
• MCs play a central role in the pathogenesis of chronic urticaria.
• Dysregulation of MCs, often due to KIT mutations, leads to mastocytosis, a malignant condition.

Purpose of the Study:

• To review MC activation mechanisms and functions in allergic diseases, chronic urticaria, and mastocytosis.
• To discuss novel biologic therapeutics targeting MCs.
• To summarize preclinical and clinical data of MC-targeted therapies.

Main Methods:

• Literature review of MC biology and therapeutic targets.
• Analysis of recent preclinical and clinical trial data for novel biologics.
• Discussion of MC activation pathways and disease involvement.

Main Results:

• MCs are implicated in allergy, chronic urticaria, and mastocytosis.
• Several novel therapeutics, including MRGPRX2 antagonists, TKIs, anti-Siglec-6, and anti-KIT mAbs, are in clinical development.
• These biologics aim to modulate MC activation or burden.

Conclusions:

• MCs are significant therapeutic targets for allergic diseases, chronic urticaria, and mastocytosis.
• Emerging biologic therapies show promise in targeting MCs and their mediators.
• Further clinical evaluation is crucial to establish the efficacy and safety of these novel MC-directed treatments.